Do you want to combat antibiotic resistance through the use of the newest and most effective drugs? Enroll in this Antivirals, Antimycotics, Antiparasitics and the Development of Antibiotic Resistance and you can delve into the characteristics of the best treatments for it"

According to the World Health Organization, "antibiotic resistance is one of the greatest threats to global health today, food security and, in general, development". As has been determined by numerous investigations carried out in the field of Biology and Infectology, microorganisms, by their nature, have an adaptive characteristic that allows them to mutate and develop immunity to the treatments that are used for palliation, decreasing drug efficacy and making it the clinical guideline for their management increasingly difficult. Despite being an intrinsic phenomenon of viruses, bacteria, fungi and parasites, the misuse and exaggeration of antibiotics has led to an acceleration of this consequence, highlighting the urgent need to develop new chemical guidelines to mitigate their effects. 

Based on this, medical professionals play a fundamental role, not only because they are the ones who establish the treatments, but because they can act conscientiously in guiding patients to correctly use different drugs. And in order for them to update them on these progress that have been made in this field in relation to super resistance and the most innovative and effective antimicrobial alternatives, TECH has designed a complete and comprehensive curriculum perfect for this. From this, arises this Antivirals, Antimycotics, Antiparasitics and the Development of Antibiotic Resistance in Antivirals, Antifungals, Antiparasitics and Antibiotic Resistance Development, a program through which you can delve into the latest advances of the different treatments, as well as the most effective clinical guidelines for combating microbial defence of viruses, bacteria, fungi and parasites.

For this purpose, it will have 500 hours of the best theoretical, practical and additional content, the latter presented in different formats: in-detail videos, research articles, complementary readings, images, dynamic summaries of each unit, FAQs and more! Everything has been compacted into a 100% online program, accessible from a state-of-the-art Virtual Campus and compatible with any device with internet connection. In this way, students will not have to worry about tight schedules or face-to-face classes, updating their knowledge in a program that adapts not only to their needs, but to the demands of the current medical sector.

A program at the forefront of Clinical Infectology, with which you will have the opportunity to update your knowledge regarding the chemical composition of different antibiotic treatments"

This Postgraduate diploma in Antivirals, Antimycotics, Antiparasitics and the Development of Antibiotic Resistance contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of case studies presented by experts in Clinical Infectology
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

Would you like to delve into the latest advances of treatments for the management of diseases such as Leishmaniasis? If the answer is yes, this program is perfect for you"

The program’s teaching staff includes professionals from the sector who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities.

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to learn in real situations.

This program is designed around Problem-Based Learning, whereby professionals must try to solve the different professional practice situations that arise during the academic year. For this purpose, the student will be assisted by an innovative interactive video system created by renowned and experienced experts. 

You will work intensively on the concept of antibiotic resistance, knowing, in-detail, the most innovative guidelines for its prevention and management”

TECH will provide you with 500 hours of the best theoretical, practical and additional content to delve into the curriculum in a personalized way and expand each section according to your needs"

This program's curriculum includes 500 hours of content, distributed between the agenda, practical cases and in many additional resources presented in different formats: research articles, complementary readings, news, images, in-detail videos, frequently asked questions, dynamic summaries of each unit, etc. The inclusion of this material has been carried out with the aim of enabling each student to contextualize theoretical information, and expand each section according to their needs and requirements.

In the Virtual Campus you will find detailed videos, research articles, complementary readings, news, self-knowledge exercises and much more material to delve into the subject in a personalized way" 

Module 1. Antivirals

1.1. General Features of Antivirals

1.1.1. Classification
1.1.2. Main Indications of Antivirals

1.2. Mechanisms of action

1.2.1. Mechanisms of Action of Antivirals

1.3. Antivirals for Hepatitis: New Recommendations and Future Research Projections

1.3.1. Specific Viral Hepatitis
1.3.2. Hepatitis B Treatment
1.3.3. Hepatitis C Treatment

1.4. Antivirals for Respiratory Infections: Current Scientific Evidence

1.4.1. Main Respiratory Viruses
1.4.2. Influenza Treatment
1.4.3. Other Respiratory System Virus Treatments

1.5. Antivirals for Herpes Viruses: Recent Changes in Management

1.5.1. Main Herpes Virus Infections
1.5.2. Herpes Simplex Infection Treatment
1.5.3. Treatment of Varicella Zoster Virus Infections

1.6. Antiretrovirals for HIV: Certainties and Controversies. Future Challenges

1.6.1. Classification of Antiretrovirals
1.6.2. Mechanisms of Action of Antiretrovirals
1.6.3. Antiretroviral Treatment of HIV Infection
1.6.4. Adverse Reactions
1.6.5. Antiretroviral Treatment Failure

1.7. Topical Antivirals

1.7.1. Main Viral Infections of the Skin and Mucous Membranes
1.7.2. Topical Antivirals

1.8. Update on Interferons: Their Use in Viral and Non-Infectious Diseases

1.8.1. Classification and Action of Interferons
1.8.2. Uses of Interferons
1.8.3. Adverse Reactions of Interferons

1.9. New Areas of Antiviral Development

1.9.1. Antibiotics in Viral Hemorrhagic Diseases
1.9.2. Future Prospects for Antiviral Chemotherapy

Module 2. Antimycotics

2.1. General Elements

2.1.1. Concept
2.1.2. Origins and Development

2.2. Classification

2.2.1. Classification According to Chemical Structure
2.2.2. Classification According to Action: Local and Systemic

2.3. Mechanisms of action

2.3.1. Mechanisms of Action of Antifungal Agents

2.4. Systemic Antifungal Agents: News on their Toxicity and their Present and Future Indications

2.4.1. Antimicrobial Spectrum
2.4.2. Pharmacokinetics and Pharmacodynamics
2.4.3. Therapeutic Uses
2.4.4. Adverse Effects
2.4.5. Presentation and Dosage

2.5. Amphotericin B: Novel Concepts in its Use

2.5.1. Mechanism of Action
2.5.2. Antimicrobial Spectrum
2.5.3. Pharmacokinetics and Pharmacodynamics
2.5.4. Therapeutic Uses
2.5.5. Adverse Effects
2.5.6. Presentation and Dosage

2.6. Deep Mycosis Treatment: Current Events and Future Perspectives

2.6.1. Aspergillosis
2.6.2. Coccidioidomycosis
2.6.3. Cryptococcosis
2.6.4. Histoplasmosis

2.7. Local Antifungals

2.7.1. Antimicrobial Spectrum
2.7.2. Pharmacokinetics and Pharmacodynamics
2.7.3. Therapeutic Uses
2.7.4. Adverse Effects
2.7.5. Presentation and Dosage

2.8. Treatment of Skin and Mucous Mycosis

2.8.1. Tinea Capitis
2.8.2. Skin Tinea
2.8.3. Onychomycosis

2.9. Liver Toxicity of Systemic Antifungal Agents: Future Challenges

2.9.1. Liver Metabolism of Antifungal Agents
2.9.2. Hepatotoxicity of Antifungal Agents

Module 3. Antiparasitics II

3.1. General Elements

3.1.1. Concept
3.1.2. Origins and Development

3.2. Classification

3.2.1. Classification by Chemical Structure
3.2.2. Classification by Action Against Different Parasites

3.3. Mechanisms of action

3.3.1. Action Mechanisms of Antiparasitics

3.4. Antiparasitics for Intestinal Parasitism: New Advances

3.4.1. Classification
3.4.2. Mechanism of Action
3.4.3. Antimicrobial Spectrum
3.4.4. Pharmacokinetics and Pharmacodynamics
3.4.5. Therapeutic Uses
3.4.6. Adverse Effects
3.4.7. Presentation and Dosage

3.5. Antimalarials: Latest WHO Recommendations

3.5.1. Classification
3.5.2. Mechanism of Action
3.5.3. Antimicrobial Spectrum
3.5.4. Pharmacokinetics and Pharmacodynamics
3.5.5. Therapeutic Uses
3.5.6. Adverse Effects
3.5.7. Presentation and Dosage

3.6. Update on Antiparasitics for Filariasis

3.6.1. Classification
3.6.2. Mechanism of Action
3.6.3. Antimicrobial Spectrum
3.6.4. Pharmacokinetics and Pharmacodynamics
3.6.5. Therapeutic Uses
3.6.6. Adverse Effects
3.6.7. Presentation and Dosage

3.7. Latest Advances in Antiparasitics for Trypanosomiasis

3.7.1. Classification
3.7.2. Mechanism of Action
3.7.3. Antimicrobial Spectrum
3.7.4. Pharmacokinetics and Pharmacodynamics
3.7.5. Therapeutic Uses
3.7.6. Adverse Effects
3.7.7. Presentation and Dosage

3.8. Antiparasitics for Schistosomiasis

3.8.1. Classification
3.8.2. Mechanism of Action
3.8.3. Antimicrobial Spectrum
3.8.4. Pharmacokinetics and Pharmacodynamics
3.8.5. Therapeutic Uses
3.8.6. Adverse Effects
3.8.7. Presentation and Dosage

3.9. Antiparasitics for Leishmaniasis

3.9.1. Classification
3.9.2. Mechanism of Action
3.9.3. Antimicrobial Spectrum
3.9.4. Pharmacokinetics and Pharmacodynamics
3.9.5. Therapeutic Uses
3.9.6. Adverse Effects
3.9.7. Presentation and Dosage

3.10. Treatment of Other Less Common Parasitosis

3.10.1. Dracunculosis
3.10.2. Quiste hidatídico
3.10.3. Other Tissue Parasites

Module 4. Antibiotic Resistance

4.1. Emergence and Development of Antibiotic Resistance

4.1.1. Concept
4.1.2. Classification
4.1.3. Origins and Development

4.2. Mechanisms of Antibiotic Resistance: An Update

4.2.1. Mechanisms of Antimicrobial Resistance
4.2.2. New Resistance Mechanisms

4.3. Staphylococcal Resistance: Yesterday, Today, and Tomorrow

4.3.1. Evolution of Staphylococcal Resistance
4.3.2. Mechanisms of Staphylococcal Resistance

4.4. Resistance of Gram-Positive Germs: Latest Recommendations

4.4.1. Evolution and Resistance of GramPositive Germs
4.4.2. Resistance Mechanisms of GramPositive Germs

4.5. Resistance of Gram-Negative Germs: Current Clinical Implications

4.5.1. Evolution of GramNegative Germ Resistance
4.5.2. Resistance Mechanisms of GramNegative Germs

4.6. Virus Resistance

4.6.1. Evolution of Virus Resistance
4.6.2. Virus Resistance Mechanisms

4.7. Fungal Resistance

4.7.1. Evolution of Fungal Resistance
4.7.2. Mechanisms of Fungal Resistance

4.8. Parasite Resistance: An Emerging Problem

4.8.1. Evolution of Parasite Resistance
4.8.2. Mechanisms of Parasite Resistance
4.8.3. Resistance to Antimalarials

4.9. New Mechanisms of Antibiotic Resistance and Superbugs

4.9.1. Emergence and Progression of Superbugs
4.9.2. New Resistance Mechanisms of Superbugs

4.10. Antibiotic Resistance Control Mechanisms and Programs

4.10.1. Antibiotic Resistance Control Strategies
4.10.2. Global Program and International Experiences in the Control of Antibiotic Resistance

Enrolling in this Postgraduate Diploma will be accessing an international medical community, thanks to which, you can stay up to date in scientific developments around the world"